Leishmaniasis, a neglected tropical disease prevalent across 90 countries, affects approximately 12 million people worldwide, with 350 million more at risk of infection. Caused by unicellular parasites known as Leishmania protozoa, the disease commonly manifests as skin sores that can develop into deep ulcers. Beyond the physical damage to the skin, leishmaniasis can leave permanent scars on patients’ faces, hands, and feet, often leading to social stigma and psychological trauma. Unfortunately, the disease predominantly strikes poor communities, where medical care is often out of reach.
While various treatments for leishmaniasis do exist, they face severe limitations. Current drugs, such as antimonial compounds and amphotericin B, are hindered by high toxicity, serious side effects, and prohibitively high costs, leaving many patients unable to complete therapy. Adding to these challenges, drug resistance is becoming increasingly common. Combined with the absence of vaccines and efficient diagnostic tools, these issues leave healthcare providers with inadequate weapons against a disease that continues to spread.
Against this backdrop, a research team led by Associate Professor Kanami Mori-Yasumoto from the Faculty of Pharmaceutical Sciences at Tokyo University of Science, Japan, has made a groundbreaking discovery that could transform leishmaniasis treatment. The team, which included co-authors Dr. Takahiro Jomori from the University of the Ryukyus, Dr. Yasuhiro Hayashi from the University of Miyazaki, Dr. Mina Yasumoto-Hirose from Tropical Technology Plus at Uruma, and Dr. Junichi Tanaka from the University of the Ryukyus, isolated 10 natural compounds from the marine sponges collected in Manza, Okinawa. Their findings were published in Volume 27 of the journal Marine Biotechnology on September 05, 2025.
The researchers analyzed extracts from Theonella sponges, focusing on a group of compounds called onnamides. Through careful laboratory testing, they discovered that several of these compounds showed remarkable effectiveness against Leishmania major, a representative species of parasite that often causes skin leishmaniasis. Among them, onnamide A and 6,7-dihydro-onnamide A were the most impressive, both demonstrating potency and a favorable safety profile far exceeding current treatments.
Further investigation into the mechanism of action of these compounds revealed another exciting finding: onnamide A appears to combat L. major through a pathway distinct from that of amphotericin B, which typically works by interacting with ergosterol in the parasite’s cell membrane. This could guide scientists to new approaches to treatment, helping them overcome existing drug resistance. Moreover, the discovery of onnamide G, whose structure was revealed for the first time in this study, also provides new insights into the structural diversity and potential mechanisms of action of onnamides.
Notably, these onnamides not only effectively killed the parasite, but also spared human cells, thanks to their low toxicity and high selectivity. These advantages position onnamides as highly promising compounds for the development of new treatments for leishmaniasis. “It may also be possible to apply these compounds to other protozoan diseases, such as Chagas disease and African sleeping sickness," adds Dr. Mori-Yasumoto, highlighting the broader impact of this study. Furthermore, onnamides may exhibit pronounced activity at low concentrations, compared to existing treatments. This adds the advantages of reducing treatment duration and dosage. However, extended analyses are required to provide definitive conclusions regarding cost-effectiveness, in vivo efficacy, and in vitro pharmacokinetics before the initiation of clinical development.
Further research is being conducted to verify the potential of onnamides as suitable lead compounds in the AMED Drug Discovery Booster program, a Japanese initiative focused on supporting scientific studies to turn promising drug candidates into new medicines. In terms of scalability, Dr. Mori-Yasumoto notes, “It may be possible to develop mass-production platforms for onnamide synthesis using modern culturing technology and symbiotic bacteria, ensuring a sustainable source.” Using symbiotic bacteria as a viable strategy can lead to scalable and environmentally responsible drug production.
Furthermore, Dr. Tanaka and Dr. Jomori of the University of the Ryukyus state, "The seas of Okinawa are home to abundant world-class biological resources. In this study, we discovered anti-leishmanial active compounds from marine sponges—treasures of the ocean—that have the potential to surpass existing drugs. Pathogens are constantly evolving, and drug resistance is an unavoidable issue. To save future patients, we are determined to continue our research in search of new 'seeds of medicine.’" They emphasized the significance of this achievement as a research outcome originating from Okinawa, while also expressing strong motivation for future work.
Overall, this work represents a major advance in addressing a long-standing global health challenge. “This research is the first step in bringing new treatment options to patients around the world and represents a significant milestone in Japan’s contribution to research on neglected tropical diseases,” concludes Dr. Mori-Yasumoto. This can significantly impact global health by expanding treatment arsenal and improving outcomes. The team’s dedication to leveraging Japan’s natural resources to tackle global medical issues offers renewed hope for millions suffering from leishmaniasis and potentially other devastating parasitic diseases.
***
Reference
DOI: 10.1007/s10126-025-10494-1
Authors: Takahiro Jomori1, Nanami Higa1, Trianda Ayuning Tyas1, Natsuki Matsuura2, Yudai Ueda2, Ayumi Suetake2, Shin Miyazaki2, Shuichi Watanabe2, Sei Arizono3, Yasuhiro Hayashi3, Ko Yasumoto4, Yuji Ise5, Toshiyuki Wakimoto6, Mina Yasumoto‑Hirose7, Junichi Tanaka1, Kanami Mori‑Yasumoto2
Affiliations: 1Department of Chemistry, Biology and Marine Science, Faculty of Science, University of the Ryukyus
2Faculty of Pharmaceutical Sciences, Tokyo University of Science
3Faculty of Agriculture, University of Miyazaki
4School of Marine Biosciences, Kitasato University
5Faculty of Human Environmental Studies, Hiroshima Shudo University
6Faculty of Pharmaceutical Sciences, Hokkaido University
7Tropical Technology Plus, Uruma,
Further Information
Dr. Kanami Mori-Yasumoto
Faculty of Pharmaceutical Sciences
Tokyo University of Science
Email: yasumoto@rs.tus.ac.jp
Dr. Takahiro Jomori
Department of Chemistry, Biology and Marine Science,
Faculty of Science, University of the Ryukyus
Email: tjomori7@cs.u-ryukyu.ac.jp
Funding information
This work was supported by a grant from the FY2022–2024 Okinawa Innovation Eco-System Joint Research Promotion Project, with contributions from a Grant-in-Aid for Research Activity Start-up (Grant no. 22K20717) from the Japan Society for the Promotion of Science (JSPS), and AMED under Grant Number JP24nk0101699.
END